Compare Franco-Nevada Corporation (FNV) vs Oscar Health Inc (OSCR) Price & Performance

Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.

The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.

Oscar Health (OSCR) trades at $33.79, down 0.65% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B projected for 2026, with profitability turning positive from a $443M loss to $551M net income. Recent earnings beats in Q1 and Q2 2026 exceeded expectations by significant margins, while analyst sentiment remains mixed with a $34.75 consensus target slightly above current levels.

OSCR presents a growth story with expanding market share in ACA plans and improved medical loss ratios, though profitability remains sensitive to medical cost trends. The stock faces near-term resistance at $35 with RSI suggesting potential overbought conditions. Key risks include execution on growth targets and healthcare cost pressures, while institutional interest remains strong with recent price target upgrades following positive guidance.